Ma Lt, L. Fiona, S. Euan, C. Norman, L. Iván, Tong Pak-chiu, Lai Wai-ming, Tse Niko
{"title":"利妥昔单抗治疗中国儿童类固醇依赖性肾病综合征","authors":"Ma Lt, L. Fiona, S. Euan, C. Norman, L. Iván, Tong Pak-chiu, Lai Wai-ming, Tse Niko","doi":"10.36959/832/393","DOIUrl":null,"url":null,"abstract":"A retrospective 5-year review was performed on 11 children (mean age of 14.6 yrs (8.1-18 yrs), 8 boys and 3 girls) who had SD or FRNS from April 2009 to April 2014. All patients were in remission for at least 4 weeks before the start of Rituximab, and they received two doses of intravenous rituximab (500 mg). Their demographics (body weight, height, renal pathology, and number of relapses a year before rituximab, previous and concomitant medical treatment) were recorded.","PeriodicalId":93263,"journal":{"name":"Annals of urology & nephrology","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Rituximab for Steroid Dependent Nephrotic Syndrome in Chinese Children\",\"authors\":\"Ma Lt, L. Fiona, S. Euan, C. Norman, L. Iván, Tong Pak-chiu, Lai Wai-ming, Tse Niko\",\"doi\":\"10.36959/832/393\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A retrospective 5-year review was performed on 11 children (mean age of 14.6 yrs (8.1-18 yrs), 8 boys and 3 girls) who had SD or FRNS from April 2009 to April 2014. All patients were in remission for at least 4 weeks before the start of Rituximab, and they received two doses of intravenous rituximab (500 mg). Their demographics (body weight, height, renal pathology, and number of relapses a year before rituximab, previous and concomitant medical treatment) were recorded.\",\"PeriodicalId\":93263,\"journal\":{\"name\":\"Annals of urology & nephrology\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-08-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of urology & nephrology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.36959/832/393\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of urology & nephrology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36959/832/393","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Rituximab for Steroid Dependent Nephrotic Syndrome in Chinese Children
A retrospective 5-year review was performed on 11 children (mean age of 14.6 yrs (8.1-18 yrs), 8 boys and 3 girls) who had SD or FRNS from April 2009 to April 2014. All patients were in remission for at least 4 weeks before the start of Rituximab, and they received two doses of intravenous rituximab (500 mg). Their demographics (body weight, height, renal pathology, and number of relapses a year before rituximab, previous and concomitant medical treatment) were recorded.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
